Overexpression of human tumor-associated antigen, RCAS1, is significantly linked to dedifferentiation of thyroid carcinoma

Oncology

Volumn 64, Issue 1, 2003, Pages 83-89

  Ito, Yasuhiro ^a   Yoshida, Hiroshi ^a   Nakano, Keiichi ^a   Kobayashi, Kaoru ^a   Yokozawa, Tamotsu ^a   Hirai, Keisuke ^a   Matsuzuka, Fumio ^a   Matsuura, Nariaki ^b   Kuma, Kanji ^a   Miyauchi, Akira ^a  

^a KUMA HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; RCAS1; Thyroid carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANAPLASTIC CARCINOMA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM; FOLLICULAR CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ANTIGENS, NEOPLASM; CARCINOMA; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 18744405355     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066517     Document Type: Article

References (29)

1. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1971;26:239-257.
2. Strater J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A, Krammer PH, Moller P: CD95(APO-1/Fas)-mediated apoptosis in colon epithelial cells: A possible role in ulcerative colitis. Gastroenterology 1997;113:160-167.
3. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184:1513-1518.
4. Giordano C, Stassi G, Maria RD, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasoco M, Testi R, Galluzzo A: A potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997;275: 960-963.
5. Matsuno T, Nakagawa K, Sasaki H, Ishine N, Inagaki M, Yagi T, Haisa M, Tanaka N, Sakagami K, Orita K: Apoptosis in acute tubular necrosis and acute renal allograft rejection. Transplant Proc 1994;26:2170-2173.
6. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-2362.
7. Ling YH, Priebe W, Perez SZ: Apoptosis induced by anthracycline antibitics in P 388 parent and multidrug-resistant cells. Cancer Res 1993;53:1845-1852.
8. Tauchi H, Sawada S: Analysis of mitotic cell death caused by radiation in mouse leukemia L5178Y cells: Apoptosis is the ultimate form of cell death following mitotic failure. Int J Radiat Biol 1994;4:449-455.
9. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
10. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-429.
11. Falk MH, Traugh BC, Debatin K-M, Klas C, Gregory CD, Rickinson AB, Calendar A, Lenoir GM, Ellwart JW, Krammer PH: Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 1992;79:3300-3306.
12. Yoshino T, Kondo E, Cao L, Takahashi K, Hayashi K, Nomura S, Akagi T: Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Blood 1994;83:1856-1861.
13. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
14. Kagi D, Ledermann B, Bruki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Henegartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369:31-37.
15. ++-independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.
16. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand G, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nature Med 1996;2:1361-1366.
17. Nakashima M, Sonoda K, Watanabe T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938-942.
18. Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, Inoue Y, Yamanaka H, Matsumura A, Iuchi K, Mori T, Okada M: Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 2000;89:488-493.
19. Takahashi H, Iizuka H, Nakashima M, Wada T, Asano K, Ishida-Yamamoto A, Watanabe T: RCAS1 antigen is highly expressed in extra-mammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. J Dermatol Sci 2001;26:140-144.
20. Noguchi K, Enjoji M, Nakamuta M, Nakashima M, Nishi H, Choi H, Taguchi K, Kotoh K, Shimada M, Sugimachi K, Tsuneyoshi M, Nawata H, Watanabe T: Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett 2001;168:197-202.
21. Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H: Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin Cancer Res 1998;4:1517-1520.
22. Sonoda K, Kaku T, Hirakawa T, Kobayashi H, Amada S, Sakai K, Nakashima M, Watanabe T, Nakano H: The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol Oncol 2000;79: 424-429.
23. Fagin JA: Molecular genetics to tumors of thyroid follicular cells; in Braverman LE, Utiger RD (eds): The Thyroid, 8th ed. Lippincott, Williams & Wilkins, 2000, pp 886-898.
24. Sakamoto A, Kasai N, Sugano H: Poorly differentiated carcinoma of the thyroid. A clinicopathological entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983;52:1849-1855.
25. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753-1760.
26. Ho YS, Tseng SC, Chin TY, Hsieh LL, Lin JD: p53 gene mutation in thyroid carcinoma. Cancer Lett 1996;103:57-63.
27. Basolo F, Pollina L, Fontaninin G, Fiore L, Pacini F, Baldanzi A: Apoptosis and proliferation in thyroid carcinoma: Correlation with bcl-2 and p53 protein expression. Br J Cancer 1997;75:537-541.
28. Heigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivery JM, Duh QY, Clark OH: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335-2342.
29. Basic N, Auersperg M, Us-Krasovec M, Golouh R, Frkkovic-Grazio S, Vodnik A: Effect of primary treatment on survival and anaplastic thyroid carcinoma. Eur J Surg Oncol 2001;27: 260-264.